Core Insights - Aprea Therapeutics has identified the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119, an oral ATR inhibitor, in the ongoing ABOYA-119 Phase 1/2a study for patients with advanced solid tumors [1][6] ATR Program - Aprea is considering further development of ATRN-119 in combination with DNA-damaging agents, radiation therapy, antibody-drug conjugates, and immune checkpoint inhibitors, based on preclinical data suggesting synergistic anti-tumor effects [2][4] - The company is pausing further enrollment in monotherapy dosing arms of ABOYA-119 while ensuring current patients continue to receive therapy without interruption [3] Clinical Data - Preliminary Phase 1 monotherapy data indicate that ATRN-119 has a favorable tolerability profile with manageable adverse events at the RP2D of 1,100 mg once daily, and shows durable disease stabilization in heavily pretreated patients across multiple tumor types [8] - The company plans to present updated data from the ABOYA-119 trial at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025 [6] WEE1 Program - Aprea is advancing its lead program, the WEE1 kinase inhibitor APR-1051, with ongoing Phase 1 studies actively enrolling patients [7][9] - Early signals of clinical benefit have been observed in patients treated with APR-1051, supporting continued dose escalation and further clinical evaluation [9] Company Overview - Aprea Therapeutics focuses on developing novel cancer therapies that target cancer cells while minimizing damage to healthy cells, aiming to reduce toxicity associated with conventional treatments [10]